Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.

Avivi I, Arcaini L, Ferretti VV, Boumendil A, Finel H, Milone G, Zaja F, Liliana D, Musso M, Didier B, Bachy E, Wattad M, Nicolas-Virelizier E, Gramatzki M, Bourhis JH, Caillot D, Haenel A, Held G, Thieblemont C, Jindra P, Pohlreich D, Guilhot F, Kroschinsky F, Wahlin B, Scheid C, Ifrah N, Berthou C, Dreger P, Montoto S, Conconi A.

Br J Haematol. 2018 Jul 9. doi: 10.1111/bjh.15454. [Epub ahead of print]

PMID:
29984825
2.

Operando spectroscopy study of the carbon dioxide electro-reduction by iron species on nitrogen-doped carbon.

Genovese C, Schuster ME, Gibson EK, Gianolio D, Posligua V, Grau-Crespo R, Cibin G, Wells PP, Garai D, Solokha V, Krick Calderon S, Velasco-Velez JJ, Ampelli C, Perathoner S, Held G, Centi G, Arrigo R.

Nat Commun. 2018 Mar 5;9(1):935. doi: 10.1038/s41467-018-03138-7.

3.

Genome Sequences of Mycobacteriophages Amgine, Amohnition, Bella96, Cain, DarthP, Hammy, Krueger, LastHope, Peanam, PhelpsODU, Phrank, SirPhilip, Slimphazie, and Unicorn.

Anders KR, Barekzi N, Best AA, Frederick GD, Mavrodi DV, Vazquez E; SEA-PHAGES, Amoh NYA, Baliraine FN, Buchser WJ, Cast TP, Chamberlain CE, Chung HM, D'Angelo WA, Farris CT, Fernandez-Martinez M, Fischman HD, Forsyth MH, Fortier AG, Gallo KF, Held GJ, Lomas MA, Maldonado-Vazquez NY, Moonsammy CH, Namboote P, Paudel S, Polley SM, Reyes GM, Rubin MR, Saha MS, Stukey J, Tobias TD, Garlena RA, Stoner TH, Cresawn SG, Jacobs-Sera D, Pope WH, Russell DA, Hatfull GF.

Genome Announc. 2017 Dec 7;5(49). pii: e01202-17. doi: 10.1128/genomeA.01202-17.

4.

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.

Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C.

Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8.

PMID:
28990173
5.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

PMID:
28643785
6.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.

Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45.

7.

Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.

Wattad M, Weber D, Döhner K, Krauter J, Gaidzik VI, Paschka P, Heuser M, Thol F, Kindler T, Lübbert M, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Köhne CH, Ringhoffer M, Wulf G, Held G, Salwender H, Benner A, Ganser A, Döhner H, Schlenk RF.

Leukemia. 2017 Jun;31(6):1306-1313. doi: 10.1038/leu.2017.23. Epub 2017 Jan 19.

PMID:
28138160
8.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia.

Schlenk RF, Frech P, Weber D, Brossart P, Horst HA, Kraemer D, Held G, Ringhoffer M, Burchardt A, Kobbe G, Götze K, Nachbaur D, Fischer T, Lübbert M, Salih HR, Salwender H, Wulf G, Koller E, Wattad M, Fiedler W, Kremers S, Kirchen H, Hertenstein B, Paschka P, Gaidzik VI, Teleanu V, Heuser M, Thol F, Döhner K, Krauter J, Ganser A, Döhner H; the German-Austrian AMLSG.

Leukemia. 2017 May;31(5):1217-1220. doi: 10.1038/leu.2017.22. Epub 2017 Jan 18. No abstract available.

9.

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.

Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P.

Leukemia. 2017 Apr;31(4):1012-1015. doi: 10.1038/leu.2017.18. Epub 2017 Jan 16. No abstract available.

PMID:
28090090
10.

Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.

Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dössinger G, Schiemann M, Lakshmipathi S, Martin K, Bunjes D, Harsdorf S, Weissinger EM, Menzel H, Verbeek M, Uharek L, Kröger N, Wagner E, Kobbe G, Schroeder T, Schmitt M, Held G, Herr W, Germeroth L, Bonig H, Tonn T, Einsele H, Busch DH, Grigoleit GU.

Leukemia. 2017 Oct;31(10):2161-2171. doi: 10.1038/leu.2017.16. Epub 2017 Jan 16.

PMID:
28090089
11.

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.

Schlenk RF, Lübbert M, Benner A, Lamparter A, Krauter J, Herr W, Martin H, Salih HR, Kündgen A, Horst HA, Brossart P, Götze K, Nachbaur D, Wattad M, Köhne CH, Fiedler W, Bentz M, Wulf G, Held G, Hertenstein B, Salwender H, Gaidzik VI, Schlegelberger B, Weber D, Döhner K, Ganser A, Döhner H; German-Austrian Acute Myeloid Leukemia Study Group.

Ann Hematol. 2016 Dec;95(12):1931-1942. Epub 2016 Oct 3.

12.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2282. doi: 10.1038/leu.2016.207. No abstract available.

PMID:
27804971
13.

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

Theis F, Corbacioglu A, Gaidzik VI, Paschka P, Weber D, Bullinger L, Heuser M, Ganser A, Thol F, Schlegelberger B, Göhring G, Köhne CH, Germing U, Brossart P, Horst HA, Haase D, Götze K, Ringhoffer M, Fiedler W, Nachbaur D, Kindler T, Held G, Lübbert M, Wattad M, Salih HR, Krauter J, Döhner H, Schlenk RF, Döhner K.

Leukemia. 2016 Nov;30(11):2248-2250. doi: 10.1038/leu.2016.185. Epub 2016 Jul 4. No abstract available.

PMID:
27375010
14.

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H.

Leukemia. 2016 Nov;30(11):2160-2168. doi: 10.1038/leu.2016.126. Epub 2016 May 3. Erratum in: Leukemia. 2016 Nov;30(11):2282.

PMID:
27137476
15.

Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes.

Vrhovac R, Labopin M, Ciceri F, Finke J, Holler E, Tischer J, Lioure B, Gribben J, Kanz L, Blaise D, Dreger P, Held G, Arnold R, Nagler A, Mohty M; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2016 Feb;51(2):186-93. doi: 10.1038/bmt.2015.221. Epub 2015 Oct 5.

PMID:
26437057
16.

MHC/Peptide-Specific Interaction of the Humoral Immune System: A New Category of Antibodies.

Held G, Luescher IF, Neumann F, Papaioannou C, Schirrmann T, Sester M, Smola S, Pfreundschuh M.

J Immunol. 2015 Nov 1;195(9):4210-7. doi: 10.4049/jimmunol.1402902. Epub 2015 Sep 28.

17.

The atomic structure of low-index surfaces of the intermetallic compound InPd.

McGuirk GM, Ledieu J, Gaudry É, de Weerd MC, Hahne M, Gille P, Ivarsson DC, Armbrüster M, Ardini J, Held G, Maccherozzi F, Bayer A, Lowe M, Pussi K, Diehl RD, Fournée V.

J Chem Phys. 2015 Aug 21;143(7):074705. doi: 10.1063/1.4928650.

PMID:
26298146
18.

The molecular basis for development of proinflammatory autoantibodies to progranulin.

Thurner L, Fadle N, Regitz E, Kemele M, Klemm P, Zaks M, Stöger E, Bette B, Carbon G, Zimmer V, Assmann G, Murawski N, Kubuschok B, Held G, Preuss KD, Pfreundschuh M.

J Autoimmun. 2015 Jul;61:17-28. doi: 10.1016/j.jaut.2015.05.002. Epub 2015 May 23.

PMID:
26005049
19.

Management of diffuse large B-cell lymphoma (DLBCL).

Kubuschok B, Held G, Pfreundschuh M.

Cancer Treat Res. 2015;165:271-88. doi: 10.1007/978-3-319-13150-4_11. Review.

PMID:
25655614
20.

Lack of awareness in both patients and physicians contributes to a high rate of late presentation in a South West German HIV patient cohort.

Kittner JM, von Bialy L, Wiltink J, Thomaidis T, Gospodinov B, Rieke A, Katz F, Discher T, Rath K, Claus B, Held G, Friese G, Schappert B, Schuchmann M, Galle PR.

Infection. 2015 Jun;43(3):299-305. doi: 10.1007/s15010-014-0719-9. Epub 2015 Jan 20.

PMID:
25600928
21.

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.

Paschka P, Schlenk RF, Gaidzik VI, Herzig JK, Aulitzky T, Bullinger L, Späth D, Teleanu V, Kündgen A, Köhne CH, Brossart P, Held G, Horst HA, Ringhoffer M, Götze K, Nachbaur D, Kindler T, Heuser M, Thol F, Ganser A, Döhner H, Döhner K.

Haematologica. 2015 Mar;100(3):324-30. doi: 10.3324/haematol.2014.114157. Epub 2015 Jan 16.

22.

Effect of irradiation distance on image contrast in epi-optoacoustic imaging of human volunteers.

Held G, Preisser S, Akarçay HG, Peeters S, Frenz M, Jaeger M.

Biomed Opt Express. 2014 Oct 1;5(11):3765-80. doi: 10.1364/BOE.5.003765. eCollection 2014 Nov 1.

23.

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Pfreundschuh M, Poeschel V, Zeynalova S, Hänel M, Held G, Schmitz N, Viardot A, Dreyling MH, Hallek M, Mueller C, Wiesen MH, Witzens-Harig M, Truemper L, Keller U, Rixecker T, Zwick C, Murawski N.

J Clin Oncol. 2014 Dec 20;32(36):4127-33. doi: 10.1200/JCO.2013.54.6861. Epub 2014 Nov 17. Erratum in: J Clin Oncol. 2015 Jun 10;33(17):1991.

PMID:
25403207
24.

Immunosuppression and monocyte subsets.

Rogacev KS, Zawada AM, Hundsdorfer J, Achenbach M, Held G, Fliser D, Heine GH.

Nephrol Dial Transplant. 2015 Jan;30(1):143-53. doi: 10.1093/ndt/gfu315. Epub 2014 Oct 13.

PMID:
25313167
25.

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, Held G, Brossart P, Lübbert M, Salih HR, Kindler T, Horst HA, Wulf G, Nachbaur D, Götze K, Lamparter A, Paschka P, Gaidzik VI, Teleanu V, Späth D, Benner A, Krauter J, Ganser A, Döhner H, Döhner K; German-Austrian AML Study Group.

Blood. 2014 Nov 27;124(23):3441-9. doi: 10.1182/blood-2014-05-578070. Epub 2014 Sep 30.

26.

Computed ultrasound tomography in echo mode for imaging speed of sound using pulse-echo sonography: proof of principle.

Jaeger M, Held G, Peeters S, Preisser S, Grünig M, Frenz M.

Ultrasound Med Biol. 2015 Jan;41(1):235-50. doi: 10.1016/j.ultrasmedbio.2014.05.019. Epub 2014 Sep 12.

PMID:
25220274
27.

Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.

Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M.

J Clin Oncol. 2014 Oct 10;32(29):3242-8. doi: 10.1200/JCO.2013.53.4537. Epub 2014 Aug 18.

PMID:
25135997
28.

Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens.

Hohloch K, Zeynalova S, Held G, Ziepert M, Loeffler M, Wulf G, Schmitz N, Pfreundschuh M, Trümper L.

Leukemia. 2014 Nov;28(11):2260-3. doi: 10.1038/leu.2014.213. Epub 2014 Jul 9. No abstract available.

PMID:
25005242
29.

Elevated serum free light chains do not predict outcome of elderly patients with aggressive CD20(+) B-cell lymphomas.

Achenbach M, Bittenbring JT, Ziepert M, Regitz E, Ott G, Rosenwald A, Pfreundschuh M, Altmann B, Held G.

Br J Haematol. 2014 Nov;167(3):430-4. doi: 10.1111/bjh.13001. Epub 2014 Jun 27. No abstract available.

PMID:
24974897
30.

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hänel M, Witzens-Harig M, Mahlberg R, Rübe C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M.

Blood. 2014 Jul 31;124(5):720-8. doi: 10.1182/blood-2013-10-535021. Epub 2014 Jun 17.

31.

Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL.

Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, Hänel M, Held G, Schmitz N, Viardot A, Schmidt C, Hallek M, Witzens-Harig M, Trümper L, Rixecker T, Zwick C.

Ann Oncol. 2014 Sep;25(9):1800-6. doi: 10.1093/annonc/mdu208. Epub 2014 Jun 13.

PMID:
24928834
32.

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.

Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF.

Blood. 2014 Jun 26;123(26):4027-36. doi: 10.1182/blood-2013-12-546283. Epub 2014 May 5. Erratum in: Blood. 2015 May 7;125(19):3037.

33.

Inactivation of protein-phosphatase 2A causing hyperphosphorylation of autoantigenic paraprotein targets in MGUS/MM is due to an exchange of its regulatory subunits.

Preuss KD, Fadle N, Regitz E, Held G, Pfreundschuh M.

Int J Cancer. 2014 Nov 1;135(9):2046-53. doi: 10.1002/ijc.28864. Epub 2014 Apr 5.

34.

Proinflammatory progranulin antibodies in inflammatory bowel diseases.

Thurner L, Stöger E, Fadle N, Klemm P, Regitz E, Kemele M, Bette B, Held G, Dauer M, Lammert F, Preuss KD, Zimmer V, Pfreundschuh M.

Dig Dis Sci. 2014 Aug;59(8):1733-42. doi: 10.1007/s10620-014-3089-3. Epub 2014 Mar 4.

PMID:
24591016
35.

First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013.

Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, Smola S, Schmidt-Chanasit J.

Euro Surveill. 2014 Jan 30;19(4). pii: 20685. No abstract available.

36.

Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma.

Held G, Murawski N, Ziepert M, Fleckenstein J, Pöschel V, Zwick C, Bittenbring J, Hänel M, Wilhelm S, Schubert J, Schmitz N, Löffler M, Rübe C, Pfreundschuh M.

J Clin Oncol. 2014 Apr 10;32(11):1112-8. doi: 10.1200/JCO.2013.51.4505. Epub 2014 Feb 3.

PMID:
24493716
37.

Over one-third of African-American MGUS and multiple myeloma patients are carriers of hyperphosphorylated paratarg-7, an autosomal dominantly inherited risk factor for MGUS/MM.

Zwick C, Held G, Auth M, Bernal-Mizrachi L, Roback JD, Sunay S, Iida S, Kuroda Y, Sakai A, Ziepert M, Ueda R, Pfreundschuh M, Preuss KD.

Int J Cancer. 2014 Aug 15;135(4):934-8. doi: 10.1002/ijc.28731. Epub 2014 Feb 4.

38.

Suboptimal dosing of rituximab in male and female patients with DLBCL.

Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N.

Blood. 2014 Jan 30;123(5):640-6. doi: 10.1182/blood-2013-07-517037. Epub 2013 Dec 2.

39.

Structure and stress of Re(1121); chiral terraces at a racemic surface.

Etman HA, Held G, Jenkins SJ, Bennett RA.

Phys Chem Chem Phys. 2013 Dec 28;15(48):20823-9. doi: 10.1039/c3cp53165a.

PMID:
24169450
40.

Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system.

Jakka G, Schuberth PC, Thiel M, Held G, Stenner F, Van Den Broek M, Renner C, Mischo A, Petrausch U.

Anticancer Res. 2013 Oct;33(10):4189-201.

PMID:
24122982
41.

Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement.

Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, Dreyling M, Hallek M, Witzens-Harig M, Fleckenstein J, Rübe C, Zwick C, Glass B, Schmitz N, Pfreundschuh M.

J Clin Oncol. 2013 Nov 10;31(32):4115-22. doi: 10.1200/JCO.2012.48.0467. Epub 2013 Sep 23.

PMID:
24062391
42.

The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.

Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B.

Blood. 2013 Aug 29;122(9):1576-82. doi: 10.1182/blood-2013-05-503847. Epub 2013 Jul 17.

43.

Bee Venom Phospholipase A2, a Good "Chauffeur" for Delivering Tumor Antigen to the MHC I and MHC II Peptide-Loading Compartments of the Dendritic Cells: The Case of NY-ESO-1.

Almunia C, Bretaudeau M, Held G, Babon A, Marchetti C, Castelli FA, Ménez A, Maillere B, Gillet D.

PLoS One. 2013 Jun 18;8(6):e67645. doi: 10.1371/journal.pone.0067645. Print 2013.

44.

EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.

Neumann F, Kaddu-Mulindwa D, Widmann T, Preuss KD, Held G, Zwick C, Roemer K, Pfreundschuh M, Kubuschok B.

Cancer Immunol Immunother. 2013 Jul;62(7):1211-22. doi: 10.1007/s00262-013-1412-z. Epub 2013 Apr 26.

PMID:
23619976
45.

Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry.

Alchi B, Jayne D, Labopin M, Demin A, Sergeevicheva V, Alexander T, Gualandi F, Gruhn B, Ouyang J, Rzepecki P, Held G, Sampol A, Voswinkel J, Ljungman P, Fassas A, Badoglio M, Saccardi R, Farge D; EBMT Autoimmune Disease Working Party members.

Lupus. 2013 Mar;22(3):245-53. doi: 10.1177/0961203312470729. Epub 2012 Dec 20. Erratum in: Lupus. 2013 May;22(6):653. Demin, Alexander [added]; Kotova, O [removed].

PMID:
23257404
46.

Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG).

Paschka P, Du J, Schlenk RF, Gaidzik VI, Bullinger L, Corbacioglu A, Späth D, Kayser S, Schlegelberger B, Krauter J, Ganser A, Köhne CH, Held G, von Lilienfeld-Toal M, Kirchen H, Rummel M, Götze K, Horst HA, Ringhoffer M, Lübbert M, Wattad M, Salih HR, Kündgen A, Döhner H, Döhner K.

Blood. 2013 Jan 3;121(1):170-7. doi: 10.1182/blood-2012-05-431486. Epub 2012 Oct 31.

47.

Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.

Kubuschok B, Pfreundschuh M, Breit R, Hartmann F, Sester M, Gärtner B, König J, Murawski N, Held G, Zwick C, Neumann F.

Hum Gene Ther. 2012 Dec;23(12):1224-36. doi: 10.1089/hum.2011.153. Epub 2012 Oct 31.

PMID:
22966960
48.

Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.

Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, Haile S, Mischo A, Held G, Thiel M, Tinguely M, Bifulco CB, Fox BA, Renner C, Petrausch U.

Gene Ther. 2013 Apr;20(4):386-95. doi: 10.1038/gt.2012.48. Epub 2012 Jun 28.

PMID:
22739387
49.

Preventing carbon contamination of optical devices for X-rays: the effect of oxygen on photon-induced dissociation of CO on platinum.

Risterucci P, Held G, Bendounan A, Silly MG, Chauvet C, Pierucci D, Beaulieu N, Sirotti F.

J Synchrotron Radiat. 2012 Jul;19(Pt 4):570-3. doi: 10.1107/S090904951202050X. Epub 2012 May 18.

PMID:
22713891
50.

Lessons of Studying TRP Channels with Antibodies.

Meissner M, Obmann VC, Hoschke M, Link S, Jung M, Held G, Philipp SE, Zimmermann R, Flockerzi V.

In: Zhu MX, editor. TRP Channels. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 6.

Supplemental Content

Support Center